肝胆期低信号HCC预测术后复发:系统综述与Meta分析
该系统综述与Meta分析纳入5项研究共718例患者,评估术前钆塞酸增强MRI肝胆期低信号HCC是否预测根治性手术(切除或肝移植)后3年内复发。结果显示肝胆期低信号HCC患者复发风险显著高于高信号者(OR 3.12,95%CI 1.27-7.68,P=0.01),提示肝胆期信号强度可作为无创预后影像生物标志物。
要点
- 术前肝胆期低信号HCC提示术后3年内复发风险约增高3倍。
- 肝胆期信号强度可作为HCC术后复发的无创预后影像标志物。
- 纳入研究总体偏倚风险低,异质性中等(I2=52%)。
核心结论
- 术前钆塞酸增强MRI肝胆期低信号HCC与根治性切除或肝移植后3年内肿瘤复发风险增高相关。
- 肝胆期HCC信号强度是潜在的无创预后影像生物标志物。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase、Cochrane Library和LILACS数据库。
- 纳入5项原始研究,共718例患者。
- 纳入标准为评估HCC肝胆期信号强度及术后至少3年复发的原始文章。
- 采用逆方差法和随机效应模型计算比值比(OR)。
- 使用QUIPS工具评估纳入文章质量,总体偏倚风险低。
诊断标准与关键数值
- 肝胆期低信号HCC患者术后3年内疾病复发OR为3.12(95%CI 1.27-7.68,P=0.01),参照为肝胆期高信号HCC患者。
- 异质性中等(I2=52%)。
临床应用与阅片要点
- 阅片时关注HCC在钆塞酸增强MRI肝胆期的信号强度,低信号者应在报告中提示复发风险可能增高。
- 肝胆期信号强度可作为术前无创预后评估的补充信息,辅助临床制定随访策略。
局限性
- 仅纳入5项研究,样本量有限。
- 异质性中等(I2=52%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: The aim of the current study was to investigate whether hypointense hepatocellular carcinoma (HCC) in the hepatobiliary phase (HBP) on gadoxetic acid-enhanced MRI at pretreatment is a potential prognostic marker for tumor recurrence within 3 years after surgery conducted for a curative purpose (resection or liver transplantation).
MATERIALS AND METHODS: Systematic review was performed in the PubMed, Embase, Cochrane Library, and LILACS databases. Original articles focused on evaluating HCC signal intensity (SI) in HBP, as well as recurrence at least 3 years after surgery were included in the study. Odds ratio (OR) was measured based on the inverse variance method and the random-effects model. The Quality in Prognosis Studies (QUIPS) tool was used to assess the quality of the included articles.
RESULTS: Five studies with 718 patients, in total, were analyzed. The odds ratio of disease recurrence in patients with hypointense HCC in the HBP, within 3 years after surgery, was 3.12 times higher than that observed in patients with hyperintense HCC in the HBP (OR 3.12; 95% CI 1.27-7.68; p = 0.01). Heterogeneity was classified as intermediate (I2 = 52%). Articles included in the review overall presented a low risk of bias.
CONCLUSION: Hypointense HCC in the HBP on gadoxetic acid-enhanced MRI at pretreatment has increased the likelihood of tumor recurrence in patients subjected to resection or liver transplantation. HCC SI in the HBP is a potential non-invasive imaging biomarker associated with patient prognosis.
引用
- Braga, Torres, Iared, et al. Does hypointense HCC in the Hepatobiliary Phase at Gadoxetate-Enhanced MRI Predict Recurrence After Surgery? A Systematic Review and Meta-analysis. Acad Radiol. 2022. PMID: 36253237. doi:10.1016/j.acra.2022.09.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。